# Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

> **NCT03267173** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Harbin Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer
- CAR

## Interventions

- **DRUG:** Chimeric antigen receptor T cell

## Key facts

- **NCT ID:** NCT03267173
- **Lead sponsor:** First Affiliated Hospital of Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-15
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2017-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267173, "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03267173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*